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SYNOPSIS 
Routine prophylactic central neck dissection for low-risk papillary thyroid carcinoma at the time of 
total thyroidectomy is more cost-effective than total thyroidectomy alone in the long term and it 
begins to become cost-effective from 9 years onwards.  
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ABSTRACT 
Background 
Although prophylactic central neck dissection (pCND) may reduce future locoregional recurrence 
after total thyroidectomy (TT) for low-risk papillary thyroid carcinoma (PTC), it is associated with 
a higher initial morbidity. We aimed to compare the long-term cost-effectiveness between TT with 
pCND (TT+pCND) and TT-alone in the institution’s perspective. 
Methods 
Our case definition was a hypothetical cohort of 100,000 non-pregnant female patients aged 50 
year-old with a 1.5cm cN0 PTC within one lobe. A Markov decision tree model was constructed to 
compare the estimated cost-effectiveness between TT+pCND and TT-alone after a 20-year period. 
Outcome probabilities, utilities and costs were estimated from the literature. The threshold for cost-
effectiveness was set at USD50,000/quality-adjusted life year (QALY). Sensitivity and threshold 
analyses were used to examine model uncertainty. 
Results 
Each patient who underwent TT+pCND instead of TT-alone cost an extra USD34.52 but gained an 
additional 0.323 QALY. In fact, in the sensitivity analysis, TT+pCND became cost-effective 9 
years after initial operation. In the threshold analysis, none of the scenarios that could change this 
conclusion appeared clinically possible or likely. On the other hand, TT+pCND became cost-saving 
(i.e. less costly and more cost-effective) at 20-year if associated permanent vocal cord palsy was 
kept ≤1.37%, permanent hypoparathyroidism ≤1.20% and/or postoperative radioiodine (RAI) 
ablation use was ≤ 73.64%.  
Conclusions 
In the institution’s perspective, routine pCND for low-risk PTC began to become cost-effective 9 
years after initial surgery and became cost-saving at 20-year if postoperative RAI use and/or 
permanent surgically complications were kept to a minimum. 
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INTRODUCTION 
Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma with its 
incidence doubled over the last two decades.1-4 However, despite good prognosis, locoregional 
recurrence (LR) is relatively common after curative surgery.5 With recognition of the step-wise 
progression of metastasis from central (level VI) to lateral compartments (levels II-V), routine 
prophylactic central neck dissection (pCND) has been advocated at the time of total thyroidectomy 
(TT) to minimize LR.6-8 Although central neck dissection (CND) is indicated in clinically-nodal 
positive disease, it remains controversial in clinically-nodal negative disease (cN0).9 There is little 
evidence to suggest patients with cN0 PTC would benefit from pCND at the time of TT 
(TT+pCND). Although a recent meta-analysis reported a 35% reduction in LR in the TT+pCND 
group, it was at the expense of higher morbidity.10  
Given that conducting an adequately-powered prospective, randomized trial comparing outcomes 
between TT+pCND and TT-alone is unlikely in the near-future and cost-effectiveness is an 
important outcome measurement between two different procedures or strategies,11 we aimed to 
determine which is a more cost-effective strategy in the long-term. To our knowledge, there has 
only been one study which specifically compared the cost-effectiveness between the two surgical 
strategies.12 It concluded that TT+pCND was less cost-effective than TT-alone.12 However, the 
literature search was limited and the quality adjustment factors used came from non-thyroid disease. 
Furthermore, as acknowledged by the authors, some operative complications were omitted and that 
omission might have favored the TT-alone strategy.12 Given these findings, we used a decision-tree 
analysis model to compare the medium to long-term cost-effectiveness between the two strategies, 
namely TT+pCND and TT-alone in a reference population with biopsy-proven cN0 PTC. 
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MATERIALS AND METHODS 
Case definition 
A hypothetical cohort of 100,000 non-pregnant female patients aged 50 year-old with an unifocal 
intrathyroidal 1.5cm cN0 PTC and with no previous thyroidectomy or neck irradiation was 
simulated in the model. 
The model 
A decision tree model using TreeAge Software Pro version 2013 (Treeage Software, Inc., 
Williamstown, MA, US) was constructed to compare the estimated long-term cost-effectiveness 
between TT+pCND and TT-alone. Appendix 1 outlines the Markov decision model over one year. 
Patients underwent one of two surgical strategies, namely TT+pCND or TT-alone, and were 
followed until death or 70 years-old whichever came earlier. The model included 3 major health 
states after primary operation, namely disease-free, alive with LR and death. In case of LR 
involving the central, lateral or central & lateral compartments, a compartment-oriented reoperation 
and RAI were offered. Patient in either strategy may suffer one of the surgical complications from 
the primary operation or reoperation.  
Probabilities 
Estimates of complications from primary operation, postoperative RAI and central and/or lateral 
recurrences after primary operation came from the available literature.8,9,18,19,23-29 Studies were 
limited to those which directly compared outcomes between the two strategies in cN0 PTC. 
Estimates of complications from reoperation and death from non-thyroid causes came from separate 
PubMed literature searches.13-19 Base-case values were derived by pooling the results of all 
retrieved studies. The annual mortality rate of female patients by 10-year age groups was quoted 
from the US Centers for Disease Control and Prevention.20 Table 1 summarizes outcome 
probabilities used.  
Cost data 
 6 
Our model only looked at the cost of two strategies from an institution’s perspective. Total cost 
included procedural cost, complication cost, and hospitalization. Indirect costs such as loss of 
productivity and wages were not included. Unit costs of TT and, initial pCND were estimated based 
on Medicare reimbursement for surgical procedure obtained from public access file from Centers 
for Medicare and Medicaid Services.21-23 Unit costs of other surgical procedures (such as 
reoperative CND and reoperative lateral selective neck dissection), RAI, surgically-related 
complications and annual routine surveillance were based on data obtained from previous cost-
effectiveness analyses.24,25 For the reoperative cases, the procedural cost already included the cost 
of fine needle aspiration. Table 1 summarizes the unit costs used.  
Effectiveness data 
Effectiveness was measured by quality-adjusted life years (QALYs) gained. QALY adjusts the life-
expectancy through the multiplication of quality of life adjustment with duration stayed at each 
health state. The quality of life adjustment is quantified by a utility score ranging from zero to one. 
Table 1 lists the utility score for each health state.  
Assumptions 
All pCNDs were assumed unilateral only and surgical resection was the only option for LR 
involving the different compartments. The LR rates under each strategy were assumed constant 
throughout the life cycle. Patients were assumed suitable and agreed for reoperation. For simplicity, 
only a maximum of one LR and one reoperation per patient were allowed. Similarly, only one 
complication was allowed for each primary operation or reoperation. Reoperative CND was 
assumed bilateral while reoperative lateral CND was assumed unilateral involving levels II-V. An 
empirical 3GBq RAI was given after each reoperation. The costs of preoperative assessment and 
surveillance were assumed the same in both groups. Full compliance was assumed for all kinds of 
assessment, treatment and surveillance.  
Base-case analysis 
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All the cost and effectiveness were discounted by an annual rate of 3%. This was consistent with 
the established guideline for cost-effectiveness analysis 26. The only outcome measurement was the 
incremental cost-effectiveness ratio (ICER). The ICER was the cost difference between TT+pCND 
and TT-alone divided by the difference in effectiveness between TT+pCND and TT-alone. A 
positive incremental cost meant TT+pCND was more costly while a positive effectiveness meant 
the TT+pCND was more effective. A strategy was said to be “cost-saving” if that strategy cost less 
and more effective over the other strategy (i.e. that strategy was dominant). The TT+pCND was 
regarded cost-effective if the ICER was below the threshold of USD50,000 per QALY gained, 
which was chosen as the threshold for cost-effectiveness based on analysis of the cost of current 
healthcare resource allocation decisions in the United states.26.  
Sensitivity analysis  
Univariate sensitivity analysis was performed to evaluate the impact of various outcome 
probabilities on the base-case analysis. Each clinical parameter varied from the lowest to the highest 
values as suggested in the literature while other parameters remained constant. Since TT+pCND 
would cost more than TT-alone, a negative incremental effectiveness meant TT-alone was dominant. 
In the multivariate sensitivity analysis, total morbidity was assumed the same between the two 
strategies. A threshold analysis was undertaken to capture the threshold clinical values at which the 
ICER of TT+pCND relative to TT-alone became zero (cost equivalence) or infinity (QALY 
equivalence). The range of threshold analysis was considerably expanded by adopting the 
theoretical range from 0 to 100%. 
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RESULTS 
Base-case analysis 
Table 2 shows the results of base-case analysis. After a 20-year period, each patient in TT+pCND 
spent an extra USD34.25 but also gained an additional 0.323 QALY over TT-alone. Therefore, 
following the base-case assumptions and model inputs, the TT+pCND was more costly but was also 
more effective than TT-alone in the institution’s perspective. The ICER of USD105.97 for 
TT+pCND relative to TT-alone was far below the recommended threshold of USD50,000 per 
QALY.  
Sensitivity analysis 
Table 2 shows the univariate and multivariate sensitivity analyses. No change in the conclusion was 
observed when key parameters such as complication rates and RAI were varied. Varying these 
parameters still yielded positive ICERs implying TT+pCND remained cost-effective or cost-saving. 
TT-alone only became cost-effective when annualized central or central & lateral recurrence rates 
under this strategy decreased to zero or when the annualized central or lateral recurrence rates under 
the TT+pCND strategy increased to 0.82% and 1.57%, respectively. Varying the number of year-
cycles or discount rate did not change the conclusion. Figure 1 shows the changes in ICER for 
TT+pCND relative to TT-alone over a 50-year period. ICER reached below the threshold of USD 
50,000 per QALY starting from 9 years onwards. In the multivariate sensitivity analysis, regardless 
of the actual value, so long as both strategies had equal total morbidity, TT+pCND was favored. 
Table 3 shows the results of the threshold analysis. To make TT-alone cost-saving, there were 7 
possible scenarios. They were annualized central recurrence in TT-alone reduced from 0.63% to 
≤0.17%, annualized central & lateral recurrence in TT-alone reduced 0.56% to ≤0.08%, permanent 
VCP in TT+pCND increased from 1.70% to ≥6.61%, permanent hypoparathyroidism in TT+pCND 
increased from 1.47% to ≥6.38%, annualized central recurrence in TT+pCND increased from 
0.22% to ≥0.71%, annualized lateral recurrence in TT+pCND from 0.36% to ≥1.03% or annualized 
central & lateral recurrence in TT+pCND increased from 0.29% to ≥0.94%. On the other hand, 
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there were many more possible scenarios to render TT+pCND cost-saving. However, in terms of 
surgical morbidity, TT+pCND became cost-saving if the associated permanent VCP could be kept 
≤1.37% or the permanent hypoparathyroidism could be kept ≤1.20%. TT+pCND was also cost-
saving when postoperative RAI use was reduced from 76.87% to ≤73.64%.
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DISCUSSION 
Performing routine pCND at the time of TT for cN0 PTC is controversial and this is reflected in the 
revised ATA guideline that recommends pCND “may be performed in patients with clinically 
uninvolved central neck lymph nodes especially for advanced primary tumors (T3 or T4)”.9 Unlike 
studies that compared surgical outcomes, 27-29 our study aimed to compare the long-term cost-
effectiveness between the two strategies. To our knowledge, there has only been one published 
study that compared cost-effectiveness and in that study, the authors concluded that TT+pCND was 
more costly and less effective (i.e. less cost-effective) than TT-alone.12 In contrast, although we did 
find TT+pCND to be more costly, it was more effective in the longer term. In our base analysis, 
TT+pCND was more cost-effective than TT-alone at 20 years. The ICER of TT+pCND relative to 
TT-alone was USD105.97/QALY which was well below the recommended threshold of 
USD50,000 per QALY and from the sensitivity analysis, the ICER reached below the 
recommended threshold 9 years after surgery (see Figure 1). These findings could be explained by 
the fact that patients in TT+pCND suffered less LR over time (see Figure 2) and that led to fewer 
expensive reoperations, fewer reoperation complications and gain in QALY over time. However, 
our study had some notable differences from the previous study.12 Firstly, outcome probabilities 
were derived from a comprehensive literature search. Secondly, our quality adjustment factors or 
utility scores were derived from studies on thyroid disease only. Thirdly, to provide a more realistic 
model, each LR was categorized into one of three locations, namely central, lateral and central & 
lateral compartments as each compartment-oriented reoperation is associated with its own unique 
outcomes and costs. Fourthly, instead of assuming the overall life-time recurrence risk as the total 
recurrence risk over the first 5 years, we annualized recurrence risk based on each of three 
compartments from previous studies.  
Clinical implications 
Based on our analyses, there are several implications relevant to clinicians. Firstly, since TT+pCND 
only becomes cost-effective 9 years after surgery, it is probably not worthwhile to perform pCND 
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on patients with a life-expectancy < 9 years (such as those in the elderly or with life-limiting co-
morbidities) because cost-effectiveness is not going to be achievable. Secondly, our data forces 
each individual surgeon to consider what difference he or she could achieve by adding pCND at the 
time of TT. Our model showed that TT+pCND is cost-effective if it could reduce the 10-year LR 
rate by 7% or 0.7% per year (from 1.57% to 0.87%) and so for a lower risk reduction, TT+pCND 
would be less or even become not cost-effective. Thirdly, our data suggests that permanent surgical 
morbidities from TT+pCND play a significant role on the cost-effectiveness of TT+pCND. Based 
on our analyses, TT+pCND is only cost-effective if the associated permanent VCP could be kept 
<2.51% or permanent hypoparathyroidism <5.88% and so if any one of these permanent surgical 
morbidities is higher, TT-alone could become cost-saving (see Table 3). 
From the threshold analyses, although there were 7 possible scenarios which could render TT-alone 
cost-saving, they were either clinically impossible or unlikely to happen. Five of them were 
considered clinically impossible because all involved having annualized central or central & lateral 
compartment recurrences in TT-alone less than in TT+pCND (0.17% vs. 0.22% and 0.08% vs. 
0.29%, respectively) and vice versa. However, since TT+pCND is already a TT, it could not 
possibly have a higher LR rate. The other 2 scenarios were clinically possible but unlikely. The first 
was if permanent VCP rate under the TT+pCND strategy increased from 1.70% to ≥6.61% while 
under the TT-alone strategy was kept at 1.22%. Although this was possible because pCND involved 
greater surgical dissection around the recurrent laryngeal nerve (RLN), an experienced surgeon is 
unlikely to cause a 3.9 times higher RLN injury rate than the same procedure without pCND. 
Similarly, an experienced surgeon is unlikely to cause a 7.5 times higher permanent 
hypoparathyroidism rate than the same procedure without pCND (≥6.38% vs. 0.85%). 
However, despite these results, we do acknowledge several shortcomings. Firstly, some of the 
assumptions might have been over-simplified. For example, in many centers, not every patient with 
proven LR requires treatment and even if treatment is indicated, there are other non-surgical options 
such as ethanol injection or radiofrequency ablation. Therefore, the actual cost of reoperations 
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under both strategies might actually be substantially less and that would have favored TT-alone in 
the long-term. Furthermore, there is data to suggest that the LR rate is probably non-linear and is 
high only during the initial 5-10 years.30 Therefore, our model might have over-estimated the 
difference in LR between the two strategies and favored TT+pCND over time. Another example of 
over-simplification was to assume one LR followed by one reoperation per patient as up to 10% of 
patients with first-time LR are expected to require more than one reoperations.31,32 However, given 
the higher risk of LR in TT-alone, this would have further favored the TT+pCND strategy. 
Secondly, despite a comprehensive literature search, selection and publication biases could not be 
completely ruled out as none of the studies examined were prospective randomized studies.  
 
CONCLUSION 
In the institution’s perspective, TT+pCND was more cost-effective than TT-alone for low-risk PTC 
in the long-term. It began to become cost-effective after 9 years from initial operation and this was 
due to fewer LR and reoperations over time. Although there were 7 possible clinical scenarios 
which might have rendered TT-alone cost-saving, none were clinically possible. TT+pCND became 
cost-saving at 20-year if associated permanent vocal cord palsy was ≤1.37%, permanent 
hypoparathyroidism was ≤1.20% and / or postoperative radioiodine (RAI) ablation use was ≤ 
73.64%.
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Table 1. Literature-based probabilities, unit cost (USD) for each service component for the care of papillary thyroid carcinoma patients and utility 
score for each health state in model 
Clinical Parameters Base case 
(%) 
Range for 
sensitivity analysis 
(%) 
Reference 
Complications from the primary operation 
- Temporary vocal cord palsy 
  - Total thyroidectomy alone 
  - Total thyroidectomy + prophylactic CND 
- Permanent vocal cord palsy 
  - Total thyroidectomy alone  
  - Total thyroidectomy + prophylactic CND 
- Temporary hypoparathyroidism 
  - Total thyroidectomy alone 
  - Total thyroidectomy + prophylactic CND 
- Permanent hypoparathyroidism 
  - Total thyroidectomy alone  
  - Total thyroidectomy + prophylactic CND 
- Hematoma formation requiring reoperation 
  - Total thyroidectomy alone  
  - Total thyroidectomy + prophylactic CND 
- Total morbidity* 
 
 
3.10 
3.28 
 
1.22 
1.70 
 
7.73 
20.64 
 
0.85 
1.47 
 
0.99 
1.79 
 
 
 
0.00 – 6.38 
0.00 – 7.26 
 
0.00 – 2.74 
0.0 – 2.51 
 
4.03 – 33.63 
8.70 – 42.86 
 
0.00 – 8.11 
0.0 – 5.88 
 
0.00 – 3.08 
0.00 – 2.50 
 
 
 
7,8,28,29,33-39 
7,8,28,29,33-39 
 
7,8,28,33-38 
7,8,28,33-38 
 
7,8,28,29,33-39 
7,8,28,29,33-39 
 
7,8,29,33-39 
7,8,29,33-39 
 
7,8,28,29,33,35-37 
7,8,28,29,33,35-37 
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  - Total thyroidectomy alone 
  - Total thyroidectomy + prophylactic CND 
13.89 
28.88 
 
Complications from reoperative CND 
- Temporary unilateral VCP 
- Temporary bilateral VCP / tracheostomy 
- Permanent unilateral VCP  
- Permanent bilateral VCP / tracheostomy 
- Temporary hypoparathyroidism 
- Permanent hypoparathyroidism 
- Hematoma 
- Chyle leakage 
- Total morbidity* 
 
4.04 
0.16 
2.70 
0.07 
17.14 
1.70 
1.10 
1.80 
28.71 
 
1.59 – 22.22 
0.03 – 4.94 
0.00 – 17.78 
0.00 – 3.16 
6.06 – 42.22 
0.00 – 5.00 
0.00 – 4.35  
0.00 – 2.22 
 
 
13-17 
13-17 
13-17 
13-17 
13-18 
13-18 
13-17 
13-15 
Complications from lateral selective neck dissection 
- Chyle leakage 
 
5.51 
 
5.8 – 5.83 
 
19,27 
Annualized locoregional recurrence rate 
- Central compartment only 
  - Total thyroidectomy alone  
  - Total thyroidectomy + prophylactic CND 
- Lateral compartment only 
  - Total thyroidectomy alone  
  - Total thyroidectomy + prophylactic CND 
- Central and lateral compartments 
  - Total thyroidectomy alone  
 
 
0.63 
0.22 
 
0.38 
0.36 
 
0.56 
 
 
0.00 – 1.83 
0.00 – 0.82 
 
0.00 – 3.73 
0.00 – 1.57 
 
0.00 – 1.87 
 
 
7,8,28,29,33-39 
7,8,28,29,33-39 
 
7,8,28,29,33-39 
7,8,28,29,33-39 
 
7,8,28,29,33-39 
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  - Total thyroidectomy + prophylactic CND 
- Overall locoregional recurrence rate  
  - Total thyroidectomy alone 
  - Total thyroidectomy + prophylactic CND 
0.29 
 
1.57 
0.87 
0.00 – 0.41 
 
 
7,8,28,29,33-39 
 
Likelihood of RAI after primary operation 
- Total thyroidectomy alone  
- Total thyroidectomy + prophylactic CND 
 
53.44 
76.87 
 
28.01 – 100.00 
58.09 – 100.00 
 
7,8,29,35-38,40,41 
7,8,29,35-38,40,41 
Number of deaths per 1000 population 
-50 – 54 
-55 – 64 
-65 – 74 
-75 – 84 
-85+ 
 
3.1 
6.4 
15.3 
41.4 
132.2 
20 
Service component for the care of PTC 
patients 
Unit cost in USD  Reference 
Surgical procedure 
- Total thyroidectomy 
- Central neck dissection (initial) 
- Central neck dissection (reoperative) 
- Lateral selective neck dissection (reoperative) 
 
5500 
513 
6482 
6482 
 
21-23 
21-23 
24 
24 
RAI ablation 
- Specialist consult, blood tests (TSH, Tg, Anti-Tg abs), 
1060 
 
24 
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recombinant TSH injections, RAI (3.3 Gbq) ablation, 
hospital stay (2 nights), post-treatment whole body scan 
Complications from primary operation or 
reoperation 
Temporary VCP+ 
 - Otolaryngology consult, laryngoscopy, follow-up 
visit, speech therapy 
Permanent VCP# 
 - Otolaryngology consult, laryngoscopy, follow-up 
visit, speech therapy, vocal cord medialization 
Tracheostomy for VCP 
Tracheostomy for permanent VCP (annual cost) 
Temporary hypoparathyroidism+ 
 - Follow-up visits, blood tests, medications 
Permanent hypoparathyroidism (annual cost)# 
 - Follow-up visits, blood tests, medications 
Chyle leak* 
Hematoma requiring neck re-exploration 
 
 
564 
 
 
10367 
 
 
22049 
592 
144 
 
863 
 
15404 
5754 
 
 
24 
 
 
25 
 
 
24 
24 
25 
 
25 
 
24 
21-23 
Routine Surveillance (annual cost) 202 24 
Health state in model Utility Score Reference 
PTC patients 
-without recurrence and complication 
 
1.00 
 
Assumption 
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-without recurrence and with permanent complication 
-with recurrence and without permanent complication 
-with recurrence and complication 
Death 
0.54 
0.41 
0.22 
0.00 
42 
42 
42 
Definition 
Abbreviations: CND = central neck dissection; RAI = radioiodine ablation; VCP = vocal cord palsy; TSH = thyroid stimulating hormone; Tg = 
thyroglobulin; Anti-Tg abs = anti-thyroglobulin auto-antibodies; PTC = papillary thyroid carcinoma; 
*patients with more than one complication were counted as one 
+ assumed an average of 2-month duration 
# includes monthly visit for the first 6 months and then thereafter 6-monthly follow-up  
* assumed to be managed conservatively  
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Table 2. Results of Base-case and Sensitivity Analysis 
    
       
    
Cost (in USD) Per 
Patient QALYs Per Patient ICER Per Patient 
Base-case Analysis 
   
    
 1 TT+pCND 11366.462 14.000 811.899 
 2 TT-alone 11332.210 13.677 828.583 
 Incremental (1 - 2) 34.252 0.323 105.966 
  
     
  
Univariate Sensitivity Analysis           
Clinical 
Parameters 
 
Parameter Range 
(%) 
Range for Incremental 
QALYs Range for ICER 
TT-alone           
Complications from primary operation 
   
  
  Temporary VCP 0.00 - 6.38 0.309 0.338 167.445 46.561 
  Permanent VCP 0.00 - 2.74 0.245 0.420 653.815 Favour pCND  
  Temporary hypoparathyroidism 4.03 - 33.63 0.306 0.442 129.256 Favour pCND  
  Permanent hypoparathyroidism 0.00 - 8.11 0.269 0.786 525.017 Favour pCND 
  Hematoma formation requiring reoperation 0.00 - 3.08 0.319 0.333 286.234 Favour pCND  
Complications from reoperative CND 
       Temporary unilateral VCP 1.59 - 22.22 0.323 0.323 112.514 57.382 
 Temporary bilateral VCP 0.02 - 4.94 0.323 0.323 120.771 Favour pCND 
  Permanent unilateral VCP 0.00 - 17.78 0.316 0.362 243.850 Favour pCND 
 Permanent bilateral VCP 0.00 - 3.16 0.323 0.331 149.934 Favour pCND 
  Temporary hypoparathyroidism 6.06 - 42.22 0.323 0.323 113.526 88.854 
  Permanent hypoparathyroidism 0.00 - 5.00 0.319 0.332 174.218 Favour pCND  
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  Hematoma formation requiring reoperation 0.00 - 4.35 0.323 0.323 135.957 17.358 
  Chyle leakage 0.00 - 2.22 0.323 0.323 237.345 75.311 
Complications from lateral neck dissection 
      Chyle leakage 5.21 - 5.83 0.323 0.323 112.958 98.508 
Radioiodine ablation after primary operation 28.01 - 100.00 0.323 0.323 939.905 Favour pCND 
Annual locoregional recurrence rates 
    
  
  Central compartment only 
0.00 - 1.83 -0.089 1.032 Favour TT Favour pCND 
  Lateral compartment only 0.00 - 3.73 0.082 2.061 4768.282 Favour pCND 
  Central & lateral compartments 
0.00 - 1.87 -0.042 1.092 Favour TT 
 
Favour pCND 
TT+pCND           
Complications from the primary operation 
   
  
  Temporary VCP 0.00 - 7.26 0.338 0.305 46.561 185.945 
  Permanent VCP 0.00 - 2.51 0.435 0.270 Favour pCND  437.836 
  Temporary hypoparathyroidism 8.70 - 42.86 0.378 0.221 45.108 299.741 
  Permanent hypoparathyroidism 0.00 - 5.88 0.420 0.033 Favour pCND  18073.707 
  Hematoma formation requiring reoperation 0.00 - 2.50 0.331 0.320 Favour pCND  234.729 
Complications from reoperative CND 
       Temporary unilateral VCP 1.59 - 22.22 0.323 0.323 102.998 127.989 
 Temporary bilateral VCP 0.03 - 4.94 0.323 0.323 99.268 337.839 
  Permanent unilateral VCP 0.00 - 17.78 0.326 0.306 45.415 466.488 
 Permanent bilateral VCP 0.00 - 3.16 0.323 0.320 86.406 943.945 
  Temporary hypoparathyroidism 6.06 - 42.22 0.323 0.323 102.539 113.723 
  Permanent hypoparathyroidism 0.00 - 5.00 0.325 0.319 76.419 164.344 
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  Hematoma formation requiring reoperation 0.00 - 4.35 0.323 0.323 92.372 146.132 
  Chyle leakage 0.00 - 2.22 0.323 0.323 46.413 119.862 
Complications from lateral neck dissection 
      Chyle leakage 5.21 - 5.83 0.323 0.323 98.960 113.440 
Radioiodine ablation after primary operation 58.09 - 100.00 0.323 0.323 Favour pCND  864.490 
Annual locoregional recurrence rate 
    
  
  Central compartment only 0.00 - 0.82 0.475 -0.071 Favour pCND  Favour TT 
  Lateral compartment only 0.00 - 1.57 0.569 -0.434 Favour pCND Favour TT 
  Central & lateral compartments 0.00 - 0.41 0.524 0.242 Favour pCND 1090.453 
              
Year Cycle 10 to 50 years 0.047 0.807 6995.449 Favour pCND  
Discount rate 0 to 5 0.508 0.239 Favour pCND  599.794 
       Multivariate Sensitivity Analysis           
Assuming equivalent total morbidity in 
primary operation between TT-alone and 
TT+pCND Value (%) 
Incremental QALYs per 
patient ICER per patient 
  Total Morbidity in TT+pCND 28.88 0.457 Favour pCND 
  Total Morbidity in TT-alone 13.89 0.460 Favour pCND 
  Total Morbidity 0.00 0.464 Favour pCND 
Abbreviations: TT = total thyroidectomy; pCND = prophylactic central neck dissection; LR = locoregional; RAI = radioiodine; 
QALYs = Quality-adjusted Life-years; ICER = Incremental cost-effectiveness ratio; VCP = vocal cord palsy 
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Table 3. Threshold analyses with incremental cost-effectiveness ratio (ICER) becoming zero or infinity 
       
Clinical Parameters 
Base-
case (%) 
Threshold Values 
(%) at ICER=0 / ∞ Values (%) at ICER>0 
Values at which TT-
alone became cost-
saving 
Values at which 
TT+pCND became 
cost-saving 
TT-alone strategy           
 
Annualized central recurrence  0.63 0.17 / 0.89 0.17 to 0.89 0.00 to 0.17 0.89 to 100.00 
 
Annualized lateral recurrence 0.38 0.57 0.00 to 0.57 NA 0.57 to 100.00 
 
Annualized central & lateral 
recurrences 0.56 0.08 / 0.77 0.08 to 0.77 0.00 to 0.08 0.77 to 100.00 
TT+pCND strategy      
 
Permanent VCP  1.70 1.37 / 6.61 1.37 to 6.61 6.61 to 100.00 0.00 to 1.37 
 
Permanent hypoparathyroidism 1.47 1.20 / 6.38 1.20 to 6.38 6.38 to 100.00 0.00 to 1.20 
 
Annualized central recurrence  0.22 0.19 / 0.71 0.19 to 0.71 0.71 to 100.00 0.00 to 0.19 
 
Annualized lateral recurrence  0.36 0.45 / 1.03 0.45 to 1.03 1.03 to 100.00 0.00 to 0.45 
 
Annualized central & lateral 
recurrences 0.29 0.37 / 0.94 0.37 to 0.94 0.94 to 100.00 0.00 to 0.37 
  Radioiodine ablation 76.87 73.64 73.64 to 100.00 NA 0.00 to 73.64 
Abbreviations: TT = total thyroidectomy; pCND = prophylactic central neck dissection; VCP = vocal cord palsy; NA = Not applicable 
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LEGENDS 
Figure 1. One way-sensitivity analysis of the incremental cost-effectiveness ratio (ICER) of total 
thyroidectomy + prophylactic central neck dissection (TT+pCND) over total thyroidectomy alone 
(TT-alone) as a function of time from primary operation (in years). The dashed line represents the 
50,000/QALY threshold for cost-effectiveness. After 9 years, TT+pCND became cost-effective 
 
 
 
 
 
 
 26 
Figure 2. Proportion of patients with recurrent disease (%) as a function of time from primary 
operation (in years) between total thyroidectomy + prophylactic central neck dissection (TT+pCND) 
and total thyroidectomy alone (TT+alone) 
 
Appendix 1. The Markov decision tree 
 
